Category Archives: Pharmacogenomics

Global Pharmacogenomics Market Report concentrates on the strong analysis of the present state of Pharmacogenomics Market which will help the readers to develop innovative strategies that will act as a catalyst for the overall growth of their industry.

The Global Pharmacogenomics Market research report of competitive analysis, statistical analysis, development trend, end-user analysis, historical data and forecast from 2020-2029. The Pharmacogenomics Market providing a comprehensive analysis of the market share, growth, size, trend, demand, outlook, classification, revenue details, competitive scenario, industry analysis, markets forecast, manufacturers, type, application, and Pharmacogenomics industry overview. The global Pharmacogenomics market report provide complete information regarding different factors driving or constraining business sector development. It gives a forecast on the estimation of the way of Pharmacogenomics market development. Key players can consider statistics, tables & figures mentioned in this report for strategic planning which lead to the success of the organizations such as Dynamic DNA Laboratories, Assurex Health Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Empire Genomics LLC, Myriad Genetics Inc, Illumina Inc, OPKO Health Inc (GeneDx), Hoffmann-La Roche AG and OneOme LLC.

This Pharmacogenomics market report provides information regarding the revenue (USD Million) and volume (Kilo Tons) for the period 2019 to 2029. It further elaborates the market drivers which contribute to the growth. It then describes the restraints that are faced by the market. The market is classified into various segments with in-depth analysis of each segment for the study period. The report classifies the market into different segments based on Technology, Application, End User, And Region. These segments are studied in detail incorporating the market estimates and forecasts at the regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

Click Here, And Download Free Sample Copy In Just One Single Step At:https://marketresearch.biz/report/pharmacogenomics-market/request-sample

****GET UPTO 25% OFF (Year Ending Offer)****

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Pharmacogenomics market with different perspectives for the purpose of providing a detailed informative and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

The Pharmacogenomics Market is segmented based on

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthersSegmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthersSegmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

Geographically, this report is segmented into several key Regions, with revenue (million USD), production, consumption, and market share and growth rate of Pharmacogenomics in these regions, from 20202 to 2029 (forecast), covering multiple geographies such as North America, South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil

Top key questions answered in this report:

1. What are the major factors influencing the growth of the market (opportunities, drivers, industry-specific challenges, growth potential, and risks)?

2. Which consumer segment accounted for the highest sales of Pharmacogenomics in 2020?

3. What are the business risks and factors concerning the market?

4. What are some of the most promising, high-growth opportunities for Pharmacogenomics market by Technology, Application, End User, And Region?

5. Which region offers the most lucrative opportunities for the market in 2020?

6. What Pharmacogenomics product types will be the most in-demand in the recent year?

7. What sales channel will account for the largest sales?

8. What are the major challenges facing the Pharmacogenomics market?

Customize Report AndInquiry For The Pharmacogenomics Market Report:https://marketresearch.biz/report/pharmacogenomics-market/#inquiry

If you wish to find more details of the report or want a customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Who Are We?

Prudour Pvt. Ltd. (https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge.

Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Our ever-growing team of experts and professionals from various streams and verticals bring along crucial tried-and-tested skills, approaches, and techniques to conduct research and analysis, and deliver accurate and reliable forecasts on all global markets. We constantly push the limits and boundaries as we surge ahead to being one among the most sought-after companies in the market research and solutions industry, and this we do with great pride. We never stop focusing on innovation and improvement, which results in significant value addition to our offerings, while at the same time we maintain stringent guidelines with regard to qualitative and quantitative analysis outputs and forecasts.

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

Find More Related Reports:

Coil Coatings Market

Extruded Snacks Market

Fluropolymer Market

Sludge Treatment Chemicals Market

Specialty Medical Chairs Market

Waste to Energy Market

Wind Turbine Market

Cold Plasma Market

Commercial Drone Market

Coriolis Meters Market

Food Packaging Technology & Equipment Market

Iron Oxide Market

Medical Foods Market

Phytonutrients Market

Sterilization Equipment Market

Read the original:
Pharmacogenomics Market Is Set To Grow During 2020 To 2029 | Value Chain, Future Guidelines and Profit Margin - True Version

Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq:IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Companys ThyGeNEXT test, representing an increase of approximately $2,400 per assay over previous reimbursement coverage. This increase in reimbursement rates reflects the expansion of the ThyGeNEXT panel to aid in identifying the appropriate patients for surgery. In 2018, Interpace processed approximately 12,500 ThyGeNEXT tests.

Prior to the new LCD code (81455) becoming effective, it was subject to a public comment period, which ended December 15, 2019, and is now subject to an analysis and review period by MACs Medical Directors. Final approval is expected during the first quarter of 2020. ThyGeNEXT has been covered by an existing LCD since it was launched in mid-2018 and its predecessor, ThyGenX, has been covered since 2014.

Jack Stover, President & CEO of Interpace, said, I am very pleased with the draft local coverage announcement and look forward to the final determination, which when approved will demonstrate the quality of our expanded assay, and most importantly supports continued reimbursement for patients and their families potentially affected by Thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpace Biopharma provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Story continues

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

See more here:
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT - Yahoo Finance

DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Red Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

This study on the red biotechnology market provides readers with a holistic market overview, through an extensive analysis of the market.

The report analyzes the market with regards to the historical and current data to provide a forecast for the period of 2019-2027. Actionable insights and findings pertaining to the red biotechnology market help report readers take major business decisions that support their long-term business growth.

The study includes the compilation of the assessment of significant market dynamics such as key industry trends and major developments carried out by leading players, along with a detailed competitive assessment. The study is divided into key sections to provide readers with an individual understanding of the various aspects of the red biotechnology market.

Key Questions Answered

Key Topics Covered

1. Global Red Biotechnology Market - Preface1.1. Market Definition and Scope1.2. Market Segmentation1.3. Key Research Objectives1.4. Research Highlights

2. Assumptions and Research Methodology2.1. Red Biotechnology Market Definition2.2. Red Biotechnology Market Taxonomy

3. Executive Summary : Global Red Biotechnology Market3.1. Introduction3.1.1. Definition3.1.2. Industry Evolution/Developments3.2. Overview3.3. Market Dynamics3.3.1. Drivers3.3.2. Restrains3.3.3. Opportunities3.4. Global Red Biotechnology Market Analysis and Forecast, 2017-20273.5. Market Revenue Projections (US$ Bn)4. Market Outlook4.1. Pipeline Analysis4.2. Mergers & Acquisitions

5. Global Red Biotechnology Market Analysis and Forecast, by Application 5.1. Introduction5.2. Key Findings/Developments, by Type 5.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2017-20275.3.1. Biopharmaceutical Production5.3.2. Gene Therapy5.3.3. Pharmacogenomics5.3.4. Genetic Testing5.4. Global Red Biotechnology Market Attractiveness Analysis, by Application

6. Global Red Biotechnology Market Analysis and Forecast, by End-user 6.1. Introduction6.2. Key Findings/Developments, by End-user 6.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2017-20276.3.1. Pharmaceutical Industry 6.3.2. CMO & CRO6.3.3. Research Institutes6.3.4. Others 6.4. Global Red Biotechnology Market Attractiveness Analysis, by End-user

7. Global Red Biotechnology Market Analysis and Forecast, by Region/sub-Region7.1. Key Findings/Developments 7.2. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region/Sub-Region, 2017-20277.2.1. North America7.2.2. Europe7.2.3. Asia-Pacific 7.2.4. Latin America7.2.5. Middle East & Africa (MEA)7.3. Global Red Biotechnology Market Attractiveness Analysis, by Region/Sub-Region

8. North America Red Biotechnology Market Analysis and Forecast

9. Europe Red Biotechnology Market Analysis and Forecast

10. Asia-Pacific Red Biotechnology Market Analysis and Forecast

11. Latin America Red Biotechnology Market Analysis and Forecast

12. Middle East & Africa Red Biotechnology Market Analysis and Forecast

13. Competition Landscape13.1. Market Player - Competition Matrix 13.2. Market Share Analysis, by Company (2018)13.3. Company Profiles13.3.1. Pfizer Inc.13.3.2. Biogen Inc.13.3.3. Amgen Inc.13.3.4. AstraZeneca PLC13.3.5. Gilead Sciences Inc.13.3.6. Celgene Corporation13.3.7. F. Hoffmann-La Roche Ltd.13.3.8. Merck KGaA13.3.9. Regeneron Pharmaceuticals Inc.13.3.10. Takeda Pharmaceutical Company Limited

For more information about this report visit https://www.researchandmarkets.com/r/xf6hwp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more here:
Insights Into the World's Red Biotechnology Market, 2017-2019 & 2027 - Emerging Opportunities, Revenue Projections, Leading Players - PRNewswire

J Mark FitzGerald,1 Eugene R Bleecker,2 Arnaud Bourdin,3 William W Busse,4 Gary T Ferguson,5 Laura Brooks,6 Peter Barker,6 Ubaldo J Martin6

1Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada; 2Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, United States; 3Department of Respiratory Diseases, Hpital Arnaud De Villeneuve, Montpellier, France; 4Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States; 5Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, United States; 6AstraZeneca, Gaithersburg, MD, United States

Correspondence: J Mark FitzGeraldThe Lung Centre, Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre, 2775 Laurel Street, Vancouver BC V5Z 1M9, CanadaTel +1604-875-4122Email mark.fitzgerald@vch.ca

Background: Benralizumab is an interleukin-5 receptor alphadirected cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma.Objective: We explored whether benralizumab efficacy was sustained after an additional year of treatment while maintaining an acceptable safety profile.Methods: Data from the pivotal 48-week SIROCCO and 56-week CALIMA studies were integrated with data from the predefined 56-week adult phase of the BORA extension study to provide a 2-year integrated efficacy and safety analysis of benralizumab. BORA enrolled patients who had completed SIROCCO or CALIMA. Patients receiving benralizumab 30 mg subcutaneously, either every 4 weeks (Q4W) or every 8 weeks (Q8W; first three doses Q4W), were assessed. Efficacy was evaluated based on baseline blood eosinophil counts from the pivotal studies (300 and Results: Mean treatment exposures were 24.3 (Q4W, n=518) and 24.6 (Q8W, n=512) months. Exacerbation frequency reductions observed in SIROCCO/CALIMA were maintained; 50% of the patients had no exacerbations during the 2-year study period (crude exacerbation rate, Q8W: 0.56 exacerbations/year for patients with blood eosinophil counts 300 cells/L). Lung function improvements with benralizumab were maintained for 2 years, as represented by increases in mean prebronchodilator forced expiratory volume in 1 second from baseline of 0.343 L and 0.364 L with 1 and 2 years of benralizumab Q8W treatment, respectively, for patients with blood eosinophil counts 300 cells/L. Health-related quality of life improvements with benralizumab observed in the pivotal studies were also sustained. Adverse events and serious adverse event rates were similar between the BORA extension and SIROCCO/CALIMA periods, with no new or unexpected occurrence of adverse events.Conclusion: This benralizumab 2-year integrated analysis further supports long-term use of benralizumab for patients with severe, uncontrolled eosinophilic asthma.

Keywords: asthma, benralizumab, clinical features, eosinophilic inflammation, interleukin-5 receptor, safety

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Excerpt from:
Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Se | JAA - Dove Medical Press

More News26 Nov 2019 | 2:49 PM

Thiruvananthapuram, Nov 26 (UNI) National Institute of Speech and Hearing (NISH) has celebrated the 70th Constitution Day at its campus in Akkulam on Tuesday.

Sabarimala, Nov 26 (UNI) As many as 8 Ayyappa devotees were injured, two of them seriously, when a huge tree fell on them while they were trekking on the Chandranandan road near Marakkuttam, here in the wee hours on Tuesday.

Mangaluru, Nov 26 (UNI) ACP Squad in an operation arrested an Indian Army imposter Manjunath Reddy who was posing himself as Indian Army Junior Commissioned officer, at a his residence in Suratkal.

Mysuru, Nov 26 (UNI) Karnataka Chief Minister BS Yediyurappa on Tuesday expressed confident that BJP would sweep the upcoming 15 Assembly seats and that would put an end to all talks around mid-term polls in the state.

Udupi, Nov 26 (UNI) District Administration and police have warned devotees and tourists about fake website created by miscreants in the name of Sri Mookambika Temple at Kollur.

Originally posted here:
Jipmer conducts JIPP 2019 - United News of India

DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Bioinformatics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The scope of the study encompasses the global bioinformatics market based on geography, category, and application. It provides a detailed analysis of recent advances in omic technologies and examines their impact on the bioinformatics market.

It discusses the ways in which bioinformatics has been utilized by the pharma and biotech industries to streamline the research and development (R&D) process and improve efficiencies. It provides a detailed analysis of the leading countries, companies, and technologies that will drive the field forward.

The report includes:

The rapid growth in raw data generation and advances in IT software and infrastructure have enabled researchers to integrate disparate datasets in order to decipher complex biological processes and develop predictive models of disease, for the purposes of identifying and validating novel biomarkers and developing precision medicines.

Since scientists unraveled the blueprint of the human genome more than 10 years ago, they have been exploring new ways to utilize omic data to understand more complex diseases. Researchers are eager to analyze as many different types of data as possible to gain a better understanding of what is happening at the cellular and molecular levels. Service providers have developed new analytical tools and IT infrastructures to enable scientists to interrogate complex data sources and quickly and efficiently disseminate information for better decision-making to achieve this goal.

More recently, improvements in cloud computing capabilities, advances in data analysis software services and the growth of NGS technologies have helped to expand the evaluation of available datasets, allowing researchers to build systems biology models of various diseases.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Global Bioinformatics Market: Overview

Chapter 4 Bioinformatics: Data Generation and Data Management

Chapter 5 Bioinformatics: Data Analysis and Software

Chapter 6 Bioinformatics: Data Processing and Storage

Chapter 7 Bioinformatics: Sequencing Services and Platforms

Chapter 8 Bioinformatics: Sequencing Applications

Chapter 9 Bioinformatics Applications in Pharmaceutical R&D

Chapter 10 Market Trends and Analysis

Chapter 11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ywqdiu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the article here:
Analysis on the World's Bioinformatics Market 2017-2019 and Forecast to 2023 - Review of Challenges & Opportunities following the Adoption of...